Technology
The future of 23andMe raises more concerns as analysis of genomic data improves
Customers of genetic data company 23andMe could also be at greater risk than they think, suggests a New York Times History This proves that the corporate’s problems could also be short-lived in comparison with the possible danger to roughly 15 million people if 23andMe is unable to proceed operating.
Certainly, with each passing day, founder and CEO Anne Wojcicki’s hope of taking 23andMe private again looks more and more out of reach. The company, which was price $6 billion when it went public in 2021, is now valued at $150 million. It’s possible deleted next month. Press reports don’t help. (Would you purchase a set?)
The company says it stays committed to “complying with the laws that govern the data we collect,” but when sooner or later it may possibly’t accomplish that, that is troubling, in keeping with a Yale biomedical professor, who notes for the Los Angeles Times that the hacked cards bank cards will be exchanged; the genome cannot. Meanwhile, in his opinion, technology that analyzes genomes is progressing. Chances are it would turn out to be more revealing, too.